Cardiovascular Drugs Market to Reflect Impressive Expansion 2024

Posted by Vikas Bahurupi on August 21st, 2018

Cardiovascular disorders or heart disorders are disorders of circulatory systems and heart. Inflammatory heart disease, hypertensive heart disease, cerebrovascular heart disease, rheumatic heart disease, and ischemic heart disease fall under the commonly diagnosed cardiovascular disorders. In most cases, the occurrence of high blood pressure leads to hypertensive heart ailments. Major effects of hypertensive heart ailments include hypertrophy, angina, coronary heart disease and heart failure. Similarly, Rheumatic heart disorders are caused by frequent rheumatic fever. In most occasions, Group A streptococcal infection lead to occurring of rheumatic fever. 

The disorder is mostly identified in children across the globe, especially in developing economies. Cerebrovascular ailment affects neurones and blood vessels of the brain. Most commonly occurring cerebrovascular disorders include stroke, transient ischemic attack (TIA), vascular dementia, and subarachnoid hemorrhage. Reduced supply of blood to the heart is a major characteristic of Ischemic heart disorders. High death rates have been registered due to ischemic heart disorders, especially in western parts of the globe. While inflammatory heart disorders are caused mainly due to virus or bacterial infections. Such type of disorders is linked with a history of Kawasaki disease or rheumatic fever.

Report For Report Sample with Table of Contents@ https://www.researchreportinsights.com/report/upsample/120124597/Cardiovascular-Drugs-Market 

Factors such as the arrival of newer and advanced drugs and growing prevalence of heart diseases are expected to drive the global cardiovascular drugs market in near future. In addition, higher occurrence of life-style diseases and rise in the global geriatric population is further contributing to the market growth. Moreover, increasing prevalence of chronic diseases such as obesity and diabetes are fueling the demand for cardiovascular drugs.

In contrast, risk of side-effects from cardiovascular drugs and stern regulatory norms are expected to pose challenges for the market growth. Likewise, the expiration of the patent for several blockbuster drugs is an additional factor anticipated to inhibit the growth of global cardiovascular market. Introduction of improved drug combinations and increasing in acquisition and mergers between pharmaceutical companies are key trends governing the global cardiovascular drug market.

Request For Report Discount@ https://www.researchreportinsights.com/report/updiscount/120124597/Cardiovascular-Drugs-Market 

On the basis of drugs, the global cardiovascular drugs market is segmented into anti-dyslipidemics drugs, anti-thrombotics drugs and anti-hypertensive drugs. The Anti-dyslipidemics drug segment is further sub-segment into Tredaptive, Lipitor, Niaspan, Zetia/Vytorin, Crestor, and TriCor/Trilipix. The Anti-hypertensive drug segment is also sub-segmented into Seloken/Toprol-XL, Diovan/Co-Diovan, Benicar/Benicar HCT, Blopress, Aprovel/CoAprovel, Edarbi, Exforge/Exforge HCT, Coversyl, Micardis/Micardis HCT, Tekturna/Rasilez, Cozaar/Hyzaar, and Norvasc. The Anti-thrombotics drug segment includes Lovenox, Plavix, Brilique/Brilinta, Pradaxa, Eliquis and Xarelto.

Key Players:

Some of the key players operating in the cardiovascular disease drug market are AstraZeneca plc, Pfizer, Inc., Sanofi S.A., Merck & Co., Daiichi Sankyo Company Limited, Novartis AG, Bayer AG, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Johnson & Johnson, United Therapeutics Corporation, Actelion Pharmaceuticals Ltd